SIRT1 and cancer: In summary, the data collected from 11 different lineages of cancer indicate that CAP (100–200 μM) acts to alternatively induce signaling pathways through SIRT1 with two distinct outcomes: survival autophagy in non-transformed cells, and the reversal of invasive phenotype, apoptotic, and autophagic death in cancer cells.